UK Markets close in 4 mins

Global Chronic Insomnia Market to 2030 - Insights, Epidemiology, and Market Forecast - ResearchAndMarkets.com

·5-min read

The "Chronic Insomnia - Market Insights, Epidemiology, and Market Forecast - 2030" drug pipelines has been added to ResearchAndMarkets.com's offering.

This report delivers an in-depth understanding of the Chronic Insomnia, historical and forecasted epidemiology as well as the market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The Chronic Insomnia market report provides current treatment practices, emerging drugs, and their market share of the individual therapies, current and forecasted Chronic Insomnia symptoms market size from 2017 to 2030 segmented by seven major markets. The report also covers current Chronic Insomnia symptoms treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities. It assesses the underlying potential of the market.

The total prevalent cases of Chronic Insomnia is increasing in 7MM during the study period, i.e., 2017-2030.

The disease epidemiology covered in the report provides historical as well as forecasted Chronic Insomnia symptoms epidemiology segmented as the Prevalent cases of Chronic Insomnia, Diagnosed Prevalent cases of Chronic Insomnia, Gender-specific cases of Chronic Insomnia, and Age-specific cases of Chronic Insomnia. The report includes the prevalent scenario of Chronic Insomnia symptoms in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2030.

Country-wise Chronic Insomnia Epidemiology

The epidemiology segment also provides the Chronic Insomnia epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

The total number of prevalent cases of Chronic Insomnia associated in 7MM countries was 5,585,128 in 2020.

Chronic Insomnia Drug Chapters

The chronic insomnia report's drug chapter segment encloses the detailed analysis of Chronic Insomnia early-stage (Phase- I, II, and III) pipeline drugs. It also helps understand the Chronic Insomnia clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

Chronic Insomnia Market Outlook

The report's Chronic Insomnia market outlook helps build a detailed comprehension of the historic, current, and forecasted Chronic Insomnia market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

This segment gives a thorough detail of Chronic Insomnia market trend of each marketed drug and early-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to the publisher, the Chronic Insomnia market in 7MM is expected to grow in the study period 2017-2030.

Regardless of the type of therapy used, chronic insomnia treatment has two primary objectives: improving sleep quality and quantity, and improving daytime impairments. Initial treatment approaches usually include at least one behavioral intervention, such as stimulus control therapy or relaxation therapy. Biofeedback therapy is also used. Cognitive Behavioral Therapy for Insomnia (CBTI), the most effective and comprehensive non-drug approach to treating insomnia, combines cognitive therapy, behavioral interventions, and sleep hygiene education. The most recent iteration of CBTI is fully automated digital CBTI (dCBTI) and does not require clinician involvement. dCBTI has the scalability to address insomnia as a public health issue. Other non-drug approaches that may have benefits for some patients include relaxation techniques and mindfulness interventions.

Scope of the Report

  • The report covers the descriptive overview of Chronic Insomnia, explaining its causes, signs and symptoms, physiology, and currently available therapies.

  • Comprehensive insight has been provided into the Chronic Insomnia epidemiology and treatment in the 7MM.

  • Additionally, an all-inclusive account of both the current and emerging therapies for Chronic Insomnia is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.

  • A detailed review of the Chronic Insomnia market; historical and forecasted is included in the report, covering drug outreach in the 7MM.

  • The report provides an edge while developing business strategies by understanding trends shaping and driving the global Chronic Insomnia market.

Reasons to Buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Chronic Insomnia market.

  • To understand the future market competition in the Chronic Insomnia market and Insightful review of the key market drivers and barriers.

  • Organize sales and marketing efforts by identifying the best opportunities for Chronic Insomnia in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.

  • Organize sales and marketing efforts by identifying the best opportunities for the Chronic Insomnia market.

  • To understand the future market competition in the Chronic Insomnia market.

Companies Mentioned

  • Eisai Inc.

  • Merck & Co.

  • Idorsia Pharmaceuticals

  • Janssen Research & Development/Minerva Neurosciences

  • Sequential Medicine Ltd.

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/6vz1ts

View source version on businesswire.com: https://www.businesswire.com/news/home/20210304005566/en/

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900